MedTrace Logo

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-01-15

Study results available
· View outcomes & findings →

Summary

This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.

The names of the study interventions involved in this study are:

* Sacituzumab govitecan (IMMU-132)
* Pembrolizumab (Keytruda®; MK-3475)

Conditions

Interventions

DRUG

Pembrolizumab

(iv) fixed dose, administered once per cycle

DRUG

Sacituzumab Govitecan

(iv) fixed dose, administered twice per cycle

Sponsors & Collaborators

Principal Investigators

  • Ana Garrido-Castro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2024-03-09
Completion
2027-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448886 on ClinicalTrials.gov